Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan, Amlodipine, and Hydrochlorothiazide in Essential Hypertension
NCT00923091Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of hydrochlorothiazide in essential hypertension (8 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in Seated Diastolic Blood Pressure at 10 weeks. Started Jun 2009; status: completed.
02
Drugs
hydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00923091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923091.